Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case...

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Tuberculosis (TB) recurrence poses a significant global health challenge, with up to 27% of patients experiencing relapse within two years.
• Indonesia faces over 7,500 recurrent TB cases annually, highlighting the need for effective management strategies.
• Recurrent TB is linked to reduced treatment success rates and increased risk of drug resistance.

Observation:

• This study systematically reviewed five cohort studies to assess the impact of fixed-dose combination (FDC) anti-TB therapy on TB recurrence.
• The review critically appraised the validity, importance, and applicability of the selected studies.

Findings:

• One study reported a relative risk (RR) of 3.97 (1.14–13.80) for TB recurrence associated with FDC therapy, with a number needed to harm of 18.
• Four other studies supported the findings, indicating a potential increase in TB recurrence risk when using FDC anti-TB therapy.

Implications:

• The findings suggest that fixed-dose combination (FDC) anti-tuberculosis therapy may be associated with a higher risk of tuberculosis recurrence compared to separate drug formulations.
• This has critical implications for clinical practice, treatment guidelines, and patient management strategies to mitigate TB recurrence.
• Further research is warranted to explore the mechanisms behind this increased risk and to optimize TB treatment regimens.